Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Registry studies have shown that advanced disease stage at transplantation is associated with inferi...
Main Authors: | Alessandrino, Emilio Paolo, Porta, Matteo G Della, Malcovati, Luca, Jackson, Christopher H, Pascutto, Cristiana, Bacigalupo, Andrea, Teresa van Lint, Maria, Falda, Michele, Bernardi, Massimo, Onida, Francesco, Guidi, Stefano, Iori, Anna Paola, Cerretti, Raffaella, Marenco, Paola, Pioltelli, Pietro, Angelucci, Emanuele, Oneto, Rosi, Ripamonti, Francesco, Rambaldi, Alessandro, Bosi, Alberto, Cazzola, Mario |
---|---|
Format: | Online |
Language: | English |
Published: |
Blackwell Publishing Ltd
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736162/ |
Similar Items
-
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
by: Gerstung, Moritz, et al.
Published: (2015) -
Importance of Classical Morphology in the Diagnosis of Myelodysplastic Syndrome
by: Invernizzi, Rosangela, et al.
Published: (2015) -
Iron overload-related heart failure in a patient with transfusion-dependent myelodysplastic syndrome reversed by intensive combined chelation therapy
by: Pinto, Valeria, et al.
Published: (2015) -
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients
by: Rambaldi, A, et al.
Published: (2012) -
Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes
by: Santini, Valeria, et al.
Published: (2011)